Luspatercept,

Form: Lyophilized powder for subcutaneous injection

Strength: 25 mg, 75 mg

Reference Brands: Reblozyl

Category: Anemia

Luspatercept is a groundbreaking erythroid maturation agent used to treat anemia in patients with beta thalassemia and myelodysplastic syndromes (MDS). Marketed under the brand name Reblozyl, it is approved by the FDA and EMA for reducing red blood cell transfusion dependence. Luspatercept is a recombinant fusion protein administered via subcutaneous injection and produced under strict GMP compliance. Ideal for pharmaceutical distributors, wholesalers, and B2B partners seeking high-demand biologics. We offer global bulk supply, regulatory support, and competitive pricing for Luspatercept. Partner with us for reliable sourcing and efficient delivery. Contact us now for Luspatercept export and distribution solutions.